Core Viewpoint - Xianjian Technology (01302) has seen a stock increase of over 4%, currently trading at 1.65 HKD, with a transaction volume of 43.52 million HKD following the announcement of regulatory approval for its G-iliacPro iliac artery stent system by the National Medical Products Administration of China [1] Group 1 - The G-iliacPro system is designed for endovascular treatment of abdominal aortic aneurysms combined with iliac artery aneurysms or isolated common iliac artery aneurysms [1] - The product aims to enhance pelvic blood supply by reconstructing the internal iliac artery, providing a more mature and comprehensive solution for clinical applications [1] - This approval represents a systematic upgrade over existing treatment options in the market [1]
先健科技现涨超4% G-iliacPro髂动脉覆膜支架系统获药监局正式注册批准